MedTrace Logo

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

NCT06041269 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 420

Last updated 2024-11-25

No results posted yet for this study

Summary

RENOIR Study: This study will evaluate the safety, tolerability, and efficacy of Rosnilimab in subjects with moderate to severe Rheumatoid Arthritis (RA)

Conditions

Interventions

DRUG

Rosnilimab

PD-1 agonist antibody

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • AnaptysBio, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2024-11-29
Completion
2025-05-30
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • Estonia
  • France
  • Georgia
  • Germany
  • Hungary
  • Italy
  • Moldova
  • Poland
  • Slovakia
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06041269 on ClinicalTrials.gov